We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Versarien Plc | LSE:VRS | London | Ordinary Share | GB00B8YZTJ80 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0015 | 4.92% | 0.032 | 0.03 | 0.034 | 0.044 | 0.03 | 0.04 | 374,020,910 | 16:40:42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 5.45M | -13.53M | -0.0058 | -0.05 | 711.97k |
Date | Subject | Author | Discuss |
---|---|---|---|
14/12/2024 09:31 | CotswoldSparky - "Chris covered the innovate loan in the recent presentation and he believes there is scope for renegotiating terms" He also stated repayments of the Innovate Loan also start when the company is projected to EBITDA positive. So there are two positives:- 1. The terms of the loan are negotiable to the point of affordability. 2. The company projects it will be profitable when the loan payments start. And these two are leaving aside the potential proceeds from the sale of Total Carbide. | pwhite73 | |
14/12/2024 07:27 | Philby, Covid disruption loans are already being paid back so are factored into the current cashflow figures. See section 31 of the Annual Report - £99k paid in 2023. Not sure your figure of £1.93M is correct - are you getting confused with the GL investment, perhaps? Chris covered the innovate loan in the recent presentation and he believes there is scope for renegotiating terms but no discussions have been had about this. neilll, A good summary. Also worth noting that AAC's losses in 2023 were £141k and the 2023 Annual report shows £468k cash used by mature businesses. A substantial amount of this will be saved due to the sale. CS | cotswoldsparky | |
14/12/2024 06:26 | Innovate loan starts to be repaid August 2025 I think. Looking at the numbers it's going to be about £460,000 a quarter for the remaining three years. There is also an outstanding Covid disruption Loan at £1.93 million. | philbyk144 | |
14/12/2024 06:05 | They will have to pay £468,000 for innovate loan each quarter from August 2025. That could also be repayment of the £1.93 million covid interruption loan. They're gonna have to kick these down the road again even with your positive outlook on cash flow it looks like the Titanic in reality | philbyk144 | |
13/12/2024 19:41 | PPS would any of the 4 posters who gave PW's clueless post an uptick care to explain why? | supernumerary | |
13/12/2024 19:39 | PW - you really are a dimwit aren't you? I've met chimpanzees with a higher brow than yours. One of the things I know that you don't (covers a lot of ground, I know) is that when you get a list of search hits, you check them for relevance. Of the links that you provided, only one of the meagre (7) results had anything meaningful on barristors, and that was a research paper from a couple of universities touting an advance in the technology that might well (ie could conceivably) have an impact in say 5-10 years. Sounds like a dead end to me, and not a coincidence that Samsung sold off related patents for what was to them (and to vrs shareholders no doubt :¬)) a pittance). 'I would imagine' - lol - I bet you would ;¬) And when you've finished imagining it, you'll post it on here as fact, so we can all have a laugh at your utter cluelessness. PS trying to patronise me is a really bad idea. | supernumerary | |
13/12/2024 18:15 | Zzzzzx you posted that before | neilll77 | |
13/12/2024 17:54 | Well after a short lived blip the share price looks to be pretty much flat and ready to continue its drop again.Same old same old for VRS.Relentless Shareholder dilution and champions league levels of value destruction. | zydecoco | |
13/12/2024 17:51 | 800k euro funding due in 1 payment this month ✔️ £242 000 plus interest due from MCK this month ✔️ £35 000 due from 1st Installment from sale of ACC due this month ✔️ Spreadex LTD were down to 2% yesterday and will be fully out today ✔️ 2 more grants from UK possibly to land too All looks pretty good to be honest | neilll77 | |
13/12/2024 17:34 | Well after a short lived blip the share price looks to be pretty much flat and ready to continue its drop again.Same old same old for VRS.Relentless Shareholder dilution and champions league levels of value destruction. | zydecoco | |
13/12/2024 17:13 | PW misrepresenting the role of Spreadex and Cantor again as though both companies are taking a judgement of their own on the worthiness of Versarien, rather than neutrally and disinterestedly processing someone else's judgement, which is what I think they were doing. | grabster | |
13/12/2024 16:50 | You wouldn't know where to search for such high brow material but I do. I would imagine the Barristors will be going into mass production shortly that's why the UK and European distribution agreement has been signed with Versarien. | pwhite73 | |
13/12/2024 16:26 | As I said - all that stuff dates to a decade ago. Anybody who suffers from the delusion that PW is occasionally right, try googling 'samsung barristor'. | supernumerary | |
13/12/2024 16:15 | ""zydecoco - Spreadex and Cantor selling is not an issue. They supported VRS with the last placing. Now that there is additional money coming in which has encouraged interest in the shares they are selling down, others are snapping them up." He is deliberately posting falsehoods now, and he knows it. I hopo newbies and gerbils are not taken in by these misleading posts. So we have a powder puff 'investor presentation', followed by a poor RNS, followed by PW pumping and posting all this rubbish. A placing is on the way!!! Same pattern as always. | the cronk | |
13/12/2024 16:12 | "Benefits of EBITDA - EBITDA indicates how well the company is managing its day-to-day operations, including its core expenses such as the cost of goods sold. As such, it is a very fair indicator of a business’s current state and potential. In some cases, it is much fairer than either gross profit or net income." | pwhite73 | |
13/12/2024 16:09 | "EBITDA is the best measurement for the performance of a company." What?? "If all costs for running the company is £1.00 and the EBITDA is £1.50p it means the company can survive forever on 50p profit because all costs are being met. The costs include salaries, interest on loans, rents, repairs, new equipment etc. How can anyone not challenge that statement? It's not correct, and he knows it!! How can anyone post this??? | the cronk | |
13/12/2024 15:29 | supernumerary - "there's really nothing of significance since PWs paper of 2012, and not the slightest indication that they can either produce or support these devices in quality and quantity." This is not true because Samsung Electronics has been working with Professor Hyun-jong Chung on the Barristor since he first published his paper in 2012. Indeed a number of his Barristor patents have been assigned to Samsung. 21 May 2012 - "Samsung develops new graphene based transistor structure...The graphene-silicon Schottky barrier, dubbed Barristor, is designed to switch current on or off by controlling the height of the barrier" Patents by Inventor Hyun-jong Chung Memory device using graphene as charge-trap layer and method of operating the same Patent number: 9525076 Abstract: A graphene memory includes a source and a drain spaced apart from each other on a conductive semiconductor substrate, a graphene layer contacting the conductive semiconductor substrate and spaced apart from and between the source and the drain, and a gate electrode on the graphene layer. A Schottky barrier is formed between the conductive semiconductor substrate and the graphene layer such that the graphene layer is used as a charge-trap layer for storing charges. Type: Grant Filed: August 6, 2013 Date of Patent: December 20, 2016 Assignee: SAMSUNG ELECTRONICS CO., LTD. Inventors: Jae-ho Lee, Hyun-jong Chung, Seong-jun Park, Kyung-eun Byun, David Seo, Hyun-jae Song, Jin-seong Heo Note the Professor's name second from left as one of the inventors. | pwhite73 | |
13/12/2024 15:04 | PW and all,See the posts below - Investors (Shareholders) want Sales, revenue and targets and milestones for the projects and business. How much income by When? It is basic stuff.The rest is just warm air. The fact that the board does not commit or even set these out tells us a lot about their capabilities. | zydecoco | |
13/12/2024 14:52 | 1m - grants are never for the full cost of the project, so the more you take on, the more you have to fill the gaps yourself. Hence more grants won't fill the missing 30%. Like you I once worked on one of these projects; we also fiddled the figures to get more of our costs paid, but it never amounted to 100%. Not sure why we did it - presumably to cover the cost of something we had to do anyway - but this isn't the case for gnano - they've left it on the shelf for years while waiting for vrs to sort out the loan so it's obviously not crucial to them. We never took on any more of that sort of work - it just tied up valuable staff while removing the possibility of getting our generous margin on normal customer-funded jobs. Argyle - if they get anything it will be a minuscule share of a minuscule share. They are portrayed as competitors to GFETs, but these are already very much a minority interest, not surprising when they cost £500 each. For a transistor, not an AI chip! The ABC site is just full of fluff - there's really nothing of significance since PWs paper of 2012, and not the slightest indication that they can either produce or support these devices in quality and quantity. Buyers for such chips expect specifications, Application Notes, support execs, SDKs etc otherwise they'll never build them into their own products. It's just another way for vrs to look as though it's making progress while actually frittering away cash on toys for the CEO. There will never be milestones or revenue targets associated with this, and I strongly suspect there'll never be revenues either, except possibly for the odd sample going to their competitors for analysis. | supernumerary | |
13/12/2024 14:52 | Festario - "Red again. Most satisfying" There is considerable interest in the stock so MM and professional players try to fleece retail shareholders. Up 44% in the morning then down 2% in the afternoon and back up 14% as I type. Stop losses are being triggered. Spreadbet firms selling shares to cash in gains and also incur losses for those betting on the shares rising. AT trades used to set reference prices. This is all part and parcel of interest rising in a once dead stock. However this is all by the bye until the company starts announcing commercial contracts with major players which hopefully will be soon. | pwhite73 | |
13/12/2024 14:25 | the graphene transistor mkt obviously fires the imagination - even for a miniscule share. nice to see the tie up. have there been any milestones or revenue numbers of any kind attached to this. watching with interest. thanks for any replies. | argyle underclap | |
13/12/2024 14:14 | Red again. Most satisfying | festario | |
13/12/2024 13:30 | pwhite - 'Everything is now beginning to fall into place as I predicted over a year ago' oh god! here we go again! i am in joint hope with you on the abc deal though - so how long should we give it until we start to hear and then see sales? | 1manchild | |
13/12/2024 13:27 | supernumeracy - i take you points. they are all valid and factually correct. i do think they have consistently gained r&d funding though and whilst the 70/30 split is right, when you take into consideration the other granted projects they are working on i would imagine it starts to cover the 30% deficit. ive been involved in similar projects myself where i have stated a resource and product cost but in reality it is all part of an overall day job cost for the multi tasking resources in question. this is my honest experience. put it this way - it is better news than anything from the mob running the main business who also employ a turn around team as they have had nothing to do with gnanomats grants. | 1manchild | |
13/12/2024 12:29 | "zydecoco - Spreadex and Cantor selling is not an issue. They supported VRS with the last placing. Now that there is additional money coming in which has encouraged interest in the shares they are selling down, others are snapping them up." Emphatic! As opposed to mere supposition. | kemche |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions